Microbicide Trials Network

MTN-001

A Phase II trial that looked at how the ARV tenofovir is absorbed in the body as either an oral tablet or a vaginal gel, as well as women’s preferences or ability to adhere to daily regimens of each approach. The study involved 144 women in the U.S., and Uganda and South Africa, who used each product daily for six weeks, as well as the two together. The final results of drug absorption and distribution studies, published in January 2013, found the gel was associated with vaginal tissue drug levels more than 130-times higher than the oral tablet; the tablet was associated with a 56-times higher concentration of active drug in blood compared to the gel. Although self-reported adherence was very high (94 percent) and most women said they liked both products, drug serum concentrations indicated only 64 percent of the women took the tablets consistently.

 

See

Tenofovir Gel Wins Out in Drug Absorption Study, but HIV Prevention Trials Tell a Different Story

30-January-2013

     

Study comparing tenofovir gel and oral tablet finds gel provides more drug to tissue

28-February-2011

  

HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study

9-July-2008

     

MTN-001 Q&A

30-January-2013

 

See Also

MTN-001 Study Protocol